HCPCS Level II
Outpatient PPS (prospective payment system), temporary
Letter C, 622 codes. CMS HCPCS Level II file dated September 23, 2026.
License: a US government work, in the public domain (Public Domain Mark 1.0).
Run it in Rivvi
Check every code on your export
Upload a claims or charge export. Rivvi flags HCPCS codes that are deleted or replaced, with the replacement and its date.
Check my exportFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Blocks
Each block is one hundred codes. Open one instead of paging the whole letter.
Codes
281 to 320 of 622
- C8919Magnetic resonance angiography without contrast, pelvis
- C8920Magnetic resonance angiography without contrast followed by with contrast, pelvis
- C8921Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete
- C8922Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study
- C8923Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography
- C8924Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study
- C8925Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, real time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report
- C8926Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report
- C8927Transesophageal echocardiography (tee) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis
- C8928Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report
- C8929Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography
- C8930Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision
- C8931Magnetic resonance angiography with contrast, spinal canal and contents
- C8932Magnetic resonance angiography without contrast, spinal canal and contents
- C8933Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents
- C8934Magnetic resonance angiography with contrast, upper extremity
- C8935Magnetic resonance angiography without contrast, upper extremity
- C8936Magnetic resonance angiography without contrast followed by with contrast, upper extremity
- C8937Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)
- C8957Intravenous infusion for therapy/diagnosis; initiation of prolonged infusion (more than 8 hours), requiring use of portable or implantable pump
- C9014Injection, cerliponase alfa, 1 mgDeleted 2018
- C9015Injection, c-1 esterase inhibitor (human), haegarda, 10 unitsDeleted 2018
- C9016Injection, triptorelin extended release, 3.75 mgDeleted 2018
- C9021Injection, obinutuzumab, 10 mgDeleted 2014
- C9022Injection, elosulfase alfa, 1mgDeleted 2014
- C9023Injection, testosterone undecanoate, 1 mgDeleted 2014
- C9024Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabineDeleted 2018
- C9025Injection, ramucirumab, 5 mgDeleted 2015
- C9026Injection, vedolizumab, 1 mgDeleted 2015
- C9027Injection, pembrolizumab, 1 mgDeleted 2015
- C9028Injection, inotuzumab ozogamicin, 0.1 mgDeleted 2018
- C9029Injection, guselkumab, 1 mgDeleted 2018
- C9030Injection, copanlisib, 1 mgDeleted 2018
- C9031Lutetium lu 177, dotatate, therapeutic, 1 mciDeleted 2018
- C9032Injection, voretigene neparvovec-rzyl, 1 billion vector genomeDeleted 2018
- C9033Injection, fosnetupitant 235 mg and palonosetron 0.25 mgDeleted 2018
- C9034Injection, dexamethasone 9%, intraocular, 1 mcgDeleted 2018
- C9035Injection, aripiprazole lauroxil (aristada initio), 1 mgDeleted 2019
- C9036Injection, patisiran, 0.1 mgDeleted 2019
- C9037Injection, risperidone (perseris), 0.5 mgDeleted 2019